Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cecile Magis-Escurra

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
The European Respiratory Journal|January 9, 2016
Deficient interleukin-17 production in response to Mycobacterium abscessus in cystic fibrosisKatharina L Becker, Jakko van Ingen, Jaap Ten Oever, et al.
The Journal of Infection|August 15, 2017
The potential of a portable, point-of-care electronic nose to diagnose tuberculosisRosarito Coronel Teixeira, Mabel Rodríguez, Nilda Jiménez de Romero, et al.
The European Respiratory Journal|April 9, 2019
Nontuberculous mycobacterial pulmonary disease and <i>Aspergillus</i> co-infection: Bonnie and Clyde?Kim Geurts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
American Journal of Respiratory and Critical Care Medicine|March 22, 2017
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not CureMartin J Dedicoat, Gunar Günther, Valeriu Crudu, et al.
Pharmaceutics|January 21, 2023
Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c TrialJuan Espinosa-Pereiro, Samiksha Ghimire, Marieke G G Sturkenboom, et al.
The European Respiratory Journal|November 3, 2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre studySanne M H Zweijpfenning, Hester van Groningen, Jakko van Ingen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2025
Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-AnalysisJuan Espinosa-Pereiro, Ana Aguiar, Eva Nara, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2019
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteriaMike Marvin Ruth, Jasper J N Sangen, Karlijn Remmers, et al.
The European Respiratory Journal|April 20, 2019
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary <i>Mycobacterium avium</i> complex diseaseSanne M H Zweijpfenning, Jodie A Schildkraut, Jordy P M Coolen, et al.
Clinical Pharmacokinetics|April 19, 2019
Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with TuberculosisAntonia Morita I Saktiawati, Marcel Harkema, Althaf Setyawan, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
The European Respiratory Journal|January 9, 2016
Deficient interleukin-17 production in response to Mycobacterium abscessus in cystic fibrosisKatharina L Becker, Jakko van Ingen, Jaap Ten Oever, et al.
The Journal of Infection|August 15, 2017
The potential of a portable, point-of-care electronic nose to diagnose tuberculosisRosarito Coronel Teixeira, Mabel Rodríguez, Nilda Jiménez de Romero, et al.
The European Respiratory Journal|April 9, 2019
Nontuberculous mycobacterial pulmonary disease and <i>Aspergillus</i> co-infection: Bonnie and Clyde?Kim Geurts, Sanne M H Zweijpfenning, Lian J Pennings, et al.
American Journal of Respiratory and Critical Care Medicine|March 22, 2017
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not CureMartin J Dedicoat, Gunar Günther, Valeriu Crudu, et al.
Pharmaceutics|January 21, 2023
Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c TrialJuan Espinosa-Pereiro, Samiksha Ghimire, Marieke G G Sturkenboom, et al.
The European Respiratory Journal|November 3, 2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre studySanne M H Zweijpfenning, Hester van Groningen, Jakko van Ingen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2025
Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-AnalysisJuan Espinosa-Pereiro, Ana Aguiar, Eva Nara, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2019
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteriaMike Marvin Ruth, Jasper J N Sangen, Karlijn Remmers, et al.
The European Respiratory Journal|April 20, 2019
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary <i>Mycobacterium avium</i> complex diseaseSanne M H Zweijpfenning, Jodie A Schildkraut, Jordy P M Coolen, et al.
Clinical Pharmacokinetics|April 19, 2019
Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with TuberculosisAntonia Morita I Saktiawati, Marcel Harkema, Althaf Setyawan, et al.
Pageof 6